{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:50:00Z","timestamp":1771267800612,"version":"3.50.1"},"posted":{"date-parts":[[2024,5,31]]},"group-title":"Cancer Biology","reference-count":46,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,5,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Multiple myeloma represents a complex hematological malignancy, characterized by its wide array of genetic and clinical events. The introduction of proteasome inhibitors, such as carfilzomib or bortezomib, into the therapeutic landscape has notably enhanced the quality of life and survival rates for patients suffering from this disease. Nonetheless, a significant obstacle in the long-term efficacy of this treatment is the inevitable development of resistance to PIs, posing a substantial challenge in managing the disease effectively. Our study investigates the molecular mechanisms behind carfilzomib resistance by analyzing multi-omics profiles from four multiple myeloma cell lines: AMO-1, KMS-12-PE, RPMI-8226 and OPM-2, together with their carfilzomib-resistant variants. We uncovered a significant downregulation of metabolic pathways linked to strong mitochondrial dysfunction in resistant cells. Further examination of patient samples identified key genes - ABCB1, RICTOR, PACSIN1, KMT2D, WEE1 and GATM - potentially crucial for resistance, guiding us towards promising carfilzomib combination therapies to circumvent resistance mechanisms. The response profiles of tested compounds have led to the identification of a network of gene interactions in resistant cells. We identified two already approved drugs, benidipine and tacrolimus, as potential partners for combination therapy with carfilzomib to counteract resistance. This discovery enhances the clinical significance of our findings.<\/jats:p>","DOI":"10.1101\/2024.05.26.595929","type":"posted-content","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T10:35:12Z","timestamp":1717151712000},"source":"Crossref","is-referenced-by-count":2,"title":["Multi-omics data integration reveals molecular mechanisms of carfilzomib resistance in multiple myeloma"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8220-5859","authenticated-orcid":false,"given":"Alina","family":"Malyutina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0234-1568","authenticated-orcid":false,"given":"Philipp","family":"Sergeev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6920-6774","authenticated-orcid":false,"given":"Julia","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-1693","authenticated-orcid":false,"given":"Juho J.","family":"Miettinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold","family":"Bolomsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1993-7309","authenticated-orcid":false,"given":"Jie","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alun O.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0608-8176","authenticated-orcid":false,"given":"Andr\u00e9","family":"Muller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5254-6089","authenticated-orcid":false,"given":"Nara","family":"Marella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"van Duin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-8726","authenticated-orcid":false,"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7480-7710","authenticated-orcid":false,"given":"Jing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4324-8706","authenticated-orcid":false,"given":"Caroline A.","family":"Heckman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024060304400579000_2024.05.26.595929v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.12.015"},{"issue":"10","key":"2024060304400579000_2024.05.26.595929v1.2","first-page":"1371","volume-title":"InMayo Clinic Proceedings","volume":"80","year":"2005"},{"key":"2024060304400579000_2024.05.26.595929v1.3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"issue":"6","key":"2024060304400579000_2024.05.26.595929v1.4","first-page":"676","volume-title":"InSeminars in oncology","volume":"43","year":"2016"},{"issue":"5","key":"2024060304400579000_2024.05.26.595929v1.5","first-page":"2516","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","year":"2008","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"8","key":"2024060304400579000_2024.05.26.595929v1.6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrclinonc.2011.63","article-title":"Treatment of multiple myeloma","volume":"8","year":"2011","journal-title":"Nature reviews Clinical oncology"},{"key":"2024060304400579000_2024.05.26.595929v1.7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma","volume":"70","year":"2018","journal-title":"Cancer treatment reviews"},{"key":"2024060304400579000_2024.05.26.595929v1.8","first-page":"1","article-title":"Bortezomib resistance in multiple myeloma is associated with increased serine synthesis","volume":"5","year":"2017","journal-title":"Cancer & metabolism"},{"issue":"6","key":"2024060304400579000_2024.05.26.595929v1.9","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/ijc.28149","article-title":"Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells","volume":"133","year":"2013","journal-title":"International Journal of Cancer"},{"key":"2024060304400579000_2024.05.26.595929v1.10","doi-asserted-by":"publisher","DOI":"10.1042\/BST20140126"},{"issue":"2","key":"2024060304400579000_2024.05.26.595929v1.11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41419-018-1219-0","article-title":"LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p","volume":"10","year":"2019","journal-title":"Cell death & disease"},{"issue":"3","key":"2024060304400579000_2024.05.26.595929v1.12","doi-asserted-by":"crossref","first-page":"e90992","DOI":"10.1371\/journal.pone.0090992","article-title":"Reversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors","volume":"9","year":"2014","journal-title":"PloS one"},{"issue":"3","key":"2024060304400579000_2024.05.26.595929v1.13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.bbrc.2019.08.163","article-title":"Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines","volume":"519","year":"2019","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"2024060304400579000_2024.05.26.595929v1.14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4086"},{"issue":"9","key":"2024060304400579000_2024.05.26.595929v1.15","first-page":"3281","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","year":"2007","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"9","key":"2024060304400579000_2024.05.26.595929v1.16","first-page":"1801","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","year":"2012","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"2","key":"2024060304400579000_2024.05.26.595929v1.17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/leu.2017.212","article-title":"Carfilzomib resistance due to ABCB1\/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma","volume":"32","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"2024060304400579000_2024.05.26.595929v1.18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/ajt.15634","article-title":"Proteasomal adaptations underlying carfilzomib-resistance in human bone marrow plasma cells","volume":"20","year":"2020","journal-title":"American Journal of Transplantation"},{"key":"2024060304400579000_2024.05.26.595929v1.19","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23387"},{"key":"2024060304400579000_2024.05.26.595929v1.20","doi-asserted-by":"publisher","DOI":"10.1126\/science.1217141"},{"key":"2024060304400579000_2024.05.26.595929v1.21","doi-asserted-by":"publisher","DOI":"10.1021\/pr2004133"},{"key":"2024060304400579000_2024.05.26.595929v1.22","unstructured":"Hupfer I. Structure and function analysis of the human Guanylate binding protein-1 (GBP-1)\u2013a novel actin binding-protein (ABP) (Doctoral dissertation, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU))."},{"issue":"2","key":"2024060304400579000_2024.05.26.595929v1.23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.4049\/jimmunol.1300377","article-title":"Guanylate binding protein 1\u2013mediated interaction of T cell antigen receptor signaling with the cytoskeleton","volume":"192","year":"2014","journal-title":"The Journal of Immunology"},{"key":"2024060304400579000_2024.05.26.595929v1.24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1519435113"},{"issue":"8","key":"2024060304400579000_2024.05.26.595929v1.25","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.biocel.2004.01.026","article-title":"CLIC-2 modulates cardiac ryanodine receptor Ca2+ release channels","volume":"36","year":"2004","journal-title":"The international journal of biochemistry & cell biology"},{"issue":"2","key":"2024060304400579000_2024.05.26.595929v1.26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s13238-016-0342-x","article-title":"Mass spectrometry based proteomics profiling of human monocytes","volume":"8","year":"2017","journal-title":"Protein & Cell"},{"key":"2024060304400579000_2024.05.26.595929v1.27","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3307"},{"issue":"1","key":"2024060304400579000_2024.05.26.595929v1.28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","year":"2022","journal-title":"Signal transduction and targeted therapy"},{"key":"2024060304400579000_2024.05.26.595929v1.29","doi-asserted-by":"publisher","DOI":"10.1002\/elps.201100212"},{"key":"2024060304400579000_2024.05.26.595929v1.30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1569-2558(03)33007-3","article-title":"Properties and physiological significance of fatty acid binding proteins","volume":"33","year":"2003","journal-title":"Advances in Molecular and Cell Biology"},{"key":"2024060304400579000_2024.05.26.595929v1.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.08.033"},{"key":"2024060304400579000_2024.05.26.595929v1.32","unstructured":"https:\/\/www.broadinstitute.org\/mitocarta\/mitocarta30-inventory-mammalian-mitochondrial-proteins-and-pathways"},{"key":"2024060304400579000_2024.05.26.595929v1.33","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022247"},{"issue":"3","key":"2024060304400579000_2024.05.26.595929v1.34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-019-0183-y","article-title":"Management of cardiovascular risk in patients with multiple myeloma","volume":"9","year":"2019","journal-title":"Blood Cancer Journal"},{"key":"2024060304400579000_2024.05.26.595929v1.35","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btt703"},{"key":"2024060304400579000_2024.05.26.595929v1.36","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02879-8"},{"key":"2024060304400579000_2024.05.26.595929v1.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2017.10.003"},{"key":"2024060304400579000_2024.05.26.595929v1.38","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.203"},{"key":"2024060304400579000_2024.05.26.595929v1.39","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0026-3"},{"issue":"3","key":"2024060304400579000_2024.05.26.595929v1.40","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3892\/ijo.2020.5086","article-title":"GBP1 promotes erlotinib resistance via PGK1-activated EMT signaling in non-small cell lung cancer","volume":"57","year":"2020","journal-title":"International Journal of Oncology"},{"key":"2024060304400579000_2024.05.26.595929v1.41","doi-asserted-by":"crossref","unstructured":"Katayama K , Noguchi K , Sugimoto Y. Regulations of P-glycoprotein\/ABCB1\/MDR1 in human cancer cells. New Journal of Science. 2014 May 20;2014.","DOI":"10.1155\/2014\/476974"},{"issue":"20","key":"2024060304400579000_2024.05.26.595929v1.42","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1182\/bloodadvances.2020003826","article-title":"Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma","volume":"5","year":"2021","journal-title":"Blood advances"},{"issue":"3","key":"2024060304400579000_2024.05.26.595929v1.43","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bjh.15521","article-title":"Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients","volume":"183","year":"2018","journal-title":"British Journal of Haematology"},{"key":"2024060304400579000_2024.05.26.595929v1.44","first-page":"535","article-title":"The role of eukaryotic and prokaryotic ABC transporter family in failure of chemotherapy","volume":"7","year":"2017","journal-title":"Frontiers in pharmacology"},{"key":"2024060304400579000_2024.05.26.595929v1.45","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0451-1"},{"issue":"19","key":"2024060304400579000_2024.05.26.595929v1.46","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1038\/s41388-020-01639-8","article-title":"The functional roles of TCA cycle metabolites in cancer","volume":"40","year":"2021","journal-title":"Oncogene"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.05.26.595929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:29:36Z","timestamp":1768458576000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.05.26.595929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":46,"URL":"https:\/\/doi.org\/10.1101\/2024.05.26.595929","relation":{},"subject":[],"published":{"date-parts":[[2024,5,31]]},"subtype":"preprint"}}